A recombinant form of the body's own 191-amino-acid growth hormone. Clinically established for growth hormone deficiency and certain wasting conditions; widely discussed off-label for body composition and anti-aging.
FDA approved for growth hormone deficiency and specific conditions (Prader-Willi, Turner syndrome, small-for-gestational-age, HIV wasting). Anti-aging and bodybuilding use is off-label and not supported by safety evidence.
Also known as: Somatropin, somatotropin, rhGH, growth hormone
Somatropin binds the growth hormone receptor — one hormone molecule engages two receptor subunits — and the conformational change activates the associated tyrosine kinase JAK2. JAK2 phosphorylates STAT5b, which enters the nucleus and drives gene transcription. GH then works two ways: directly through the receptor in target tissues (for example lipolysis in fat, effects on glucose handling) and indirectly by stimulating the liver and local tissues to produce IGF-1, which mediates much of the anabolic, bone and muscle growth.
In genuine deficiency, somatropin reliably improves growth, body composition and metabolic parameters and raises IGF-1 — this is well established across approved indications. What is not established is the popular use case: supraphysiologic dosing for muscle gain or anti-aging has no favourable long-term safety evidence, and chronically elevated IGF-1 raises theoretical cancer-risk concerns. GH/IGF-1 signalling also has documented roles in bone metabolism.
We report both positive and negative trial results. For exact study protocols, read the sources — we cite them rather than repackage them.
Bars reflect the strength & volume of research evidence for each use — not a guarantee of results.
Fluid retention (swelling of hands and feet), joint pain, carpal tunnel syndrome, raised blood glucose and insulin resistance, and hypothyroidism. Pancreatitis is rare but serious. At supraphysiologic exposure these are more frequent and more severe.
GHRH analogs (sermorelin, CJC-1295) and GH secretagogues (ipamorelin, MK-677) — discussed as alternatives that stimulate the body's own pulsatile GH release upstream, rather than supplying the hormone directly. IGF-1 — the downstream mediator of many GH effects.
Mechanistic context only — we don't publish combinations, amounts or protocols.
Versus GH secretagogues and GHRH analogs: HGH is the exogenous hormone itself, which bypasses and suppresses natural pulsatile secretion, whereas secretagogues stimulate endogenous release and preserve more physiological pulsatility and feedback.
Both — directly via the GH receptor and JAK2/STAT5b, and indirectly by stimulating IGF-1, which mediates much of the anabolic effect.
GH deficiency in children and adults, Prader-Willi syndrome, Turner syndrome, small-for-gestational-age short stature, and HIV-associated wasting.
No. Supraphysiologic use for anti-aging or bodybuilding lacks favourable long-term safety data and carries metabolic and IGF-1-related risks.
No reviews yet. If you've used HGH, be the first to share what it helped with and any side effects.
⚠️ Educational research information only — not medical advice. Many peptides are sold strictly for laboratory research and are not approved treatments. The evidence scores reflect research interest and strength, not efficacy or safety for any individual. Always consult a qualified professional.